Mycophenolate mofetil tablets for uveitis: a review of the comparative clinical and cost-effectiveness
Canadian Agency for Drugs and Technologies in Health
Record ID 32011000939
English
Authors' recommendations:
Evidence for the relative clinical benefit and safety of mycophenolate mofetil is limited and suggests some possible benefit versus azathioprine, and differing results versus methotrexate, however these results are inconclusive. No evidence for the cost-effectiveness of mycophenolate mofetil relative to other treatments in uveitis was identified.
Details
Project Status:
Completed
Year Published:
2011
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Anti-Inflammatory Agents, Non-Steroidal
- Mycophenolic Acid
- Uveitis
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.